Table 1 Duration of maternally derived antibodies (MDA) for each infectious agent included in this review

SIV

NV

Experimental

7–8

[65]

V

Experimental

10

[23]

V

Experimental

9–14

[67]

V

Field

7–10

[69]

V

Experimental

10

[66]

V

Experimental

13–16

[68]

PRRSV

V

Field

4

[79]

NV

Experimental

4–8

[77]

U

Field

6–10

[80]

U

Field

2–8

[81]

U

Field

6–8

[72]

V

Experimental

7–11

[71]

V

Experimental

7–8

[78]

V

Experimental

3–8

[82]

PCV-2

NV

Experimental

4–11

[93]

U

Experimental

4–11

[96]

NV

Field

10

[95]

V

Field

4–12

[60]

V

Field

7–12

[21]

NV

Experimental

8

[94]

M. hyopneumoniae

NV

Field

4–9

[20]

V

Experimental

2–7

[109]

A. pleuropneumoniae

U

Experimental

9–12

[19]

NV

Field

8–10

[122]

NV

Experimental

2–8

[18]

NV

Experimental

10

[123]

NV

Field

3–7

[124]